Is Acemini on Medicare? Interpretation of reimbursement conditions and latest policies

As of now, Asciminib has not been fully included in China’s national medical insurance directory. Although the drug has been approved and marketed in European and American countries and has become an important treatment for patients with chronic myelogenous leukemia (CML), especially those with the T315I mutation, the medical insurance policy in the Chinese market still needs to be further clarified. The current price of acemini is relatively high, which makes it a treatment burden for some patients. Therefore, whether to include it in medical insurance has become the focus of attention of the majority of patients and medical workers.

In European and American countries, aximini, as a new generation of tyrosine kinase inhibitors, has been widely recognized for its clinical application, especially in patients with drug-resistant CML.The therapeutic effect is remarkable. Due to its unique efficacy, Assimini is covered by medical insurance in some areas. However, due to the high cost of drugs, patients usually need to go through special reimbursement channels or clinical drug applications to obtain treatment, and applicable patient groups need to meet certain medical insurance policy conditions.

In China, since Assimini has not yet entered the market, there is no news on whether the drug will be included in the medical insurance catalog and the specific reimbursement conditions. Usually, the criteria for drugs to enter medical insurance include factors such as clinical efficacy, economics of the drug, patient affordability, and the population using the drug. For Asiminib, it is mainly suitable for chronic myelogenous leukemia (especially those patients who are resistant to traditional TKIs). This group of patients is relatively small, so the social demand for the drug and the allocation of medical resources may need to be further considered at the policy level.

Currently, Assimini’s medical insurance reimbursement issues mainly depend on the specific policies of the region where the patient is located. To enter medical insurance, patients usually need to meet certain diagnosis and treatment standards, such as confirming the BCR-ABL1 gene mutation type, and the drug may be suitable for patients with specific types of chronic myelogenous leukemia. For specific reimbursement ratios and conditions, please refer to the policies issued by the Medical Insurance Bureau.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib